These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2501268)

  • 21. In vitro synergy of ciprofloxacin and three other antibiotics against Bacteroides fragilis.
    Esposito S; Gupta A; Thadepalli H
    Drugs Exp Clin Res; 1987; 13(8):489-92. PubMed ID: 3428131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility of anaerobic bacteria to five antimicrobial agents and demonstration of resistance of Bacteroides fragilis to clindamycin.
    Sofianou D; Douboyas J; Papapanagiotou J; Paradelis AG
    Methods Find Exp Clin Pharmacol; 1982; 4(3):173-7. PubMed ID: 7121128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.
    Aoyama H; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():99-114. PubMed ID: 2849604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Activity of seven antimicrobial agents against "Bacteroides fragilis" (author's transl)].
    Tytgat F
    Ann Microbiol (Paris); 1980; 131(1):39-44. PubMed ID: 6899739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of fleroxacin and 14 other antimicrobials against slime- and non-slime-producing Staphylococcus epidermidis.
    Kropec A; Daschner F
    Chemotherapy; 1989; 35(5):351-4. PubMed ID: 2507234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Susceptibility of the Bacteroides fragilis group to 10 antibiotics. Results of 4 laboratories in Austria].
    Mittermayer H; Rotter M; Riezinger F; Thiel W; Stanek G
    Zentralbl Bakteriol Mikrobiol Hyg A; 1986 Nov; 262(4):500-11. PubMed ID: 3799095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria.
    Salfinger M; Hohl P; Kafader FM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():55-63. PubMed ID: 3144550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
    Oh H; El Amin N; Davies T; Appelbaum PC; Edlund C
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1977-81. PubMed ID: 11408211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group.
    García-Rodriguez JA; García Sánchez JE; Trujillano I; Sánchez de San Lorenzo A
    J Antimicrob Chemother; 1991 May; 27(5):599-606. PubMed ID: 1885418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Timed bacteriostatic and bactericidal activities of cefmetazole against selected gram-negative bacteria].
    Masuda G; Young C; Negishi M; Watanabe T; Yamazaki E; Motegi K
    Jpn J Antibiot; 1982 Sep; 35(9):2288-92. PubMed ID: 6754988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
    Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
    Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The in-vitro activity of metronidazole against Enterobacteriaceae alone and in mixed cultures with Bacteroides fragilis.
    Moran FJ; Perez C; Hurtado C; Blanco MT; Prieto J
    J Antimicrob Chemother; 1987 Nov; 20(5):657-61. PubMed ID: 3429370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro activity of ciprofloxacin combined with flomoxef against Bacteroides fragilis, compared with that of ciprofloxacin combined with clindamycin.
    Kato K; Iwai S; Sato T; Harada T; Nakagawa Y; Iwanaga H; Ito Y; Takayama T
    J Infect Chemother; 2002 Jun; 8(2):190-3. PubMed ID: 12111577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Legionella pneumophila multiplication within human macrophages by fleroxacin.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():49-54. PubMed ID: 3144549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fleroxacin (Ro 23-6240): activity in vitro against 355 enteropathogenic and non-fermentative gram-negative bacilli and Legionella pneumophila.
    Hohl P; von Graevenitz A; Zollinger-Iten J
    J Antimicrob Chemother; 1987 Sep; 20(3):373-8. PubMed ID: 3119553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacteroides fragilis group: trends in resistance.
    Fille M; Mango M; Lechner M; Schaumann R
    Curr Microbiol; 2006 Feb; 52(2):153-7. PubMed ID: 16450067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial activity of SMAP-29 against the Bacteroides fragilis group and clostridia.
    Arzese A; Skerlavaj B; Tomasinsig L; Gennaro R; Zanetti M
    J Antimicrob Chemother; 2003 Sep; 52(3):375-81. PubMed ID: 12917245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rate of bactericidal activity for Branhamella catarrhalis of fleroxacin compared with that of amoxycillin-clavulanic acid.
    Yourassowsky E; Van der Linden MP; Lismont MJ; Crokaert F; Glupczynski Y
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():43-7. PubMed ID: 3144548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of sub-minimal inhibitory concentrations of ciprofloxacin and fleroxacin on the bacterial capsular antigen and opsonophagocytosis by human polymorphonuclear leukocytes.
    Keller N; Raponi G; Hoepelman IM; Overbeek BP; Rozenberg-Arska M; Verhoef J
    Zentralbl Bakteriol; 1991 Jan; 274(4):519-26. PubMed ID: 1907453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.